In this study, we have evaluated (1) the antitumour effect of everolimus on different human cancer cell lines, sensitive or resistant to EGFR inhibitors, in vitro and in nude mice; (2) the possibility to restore sensitivity to EGFR inhibitors, using everolimus in combination with gefitinib or cetuximab; (3) the effect of treatment on signalling pathways and VEGF. Here, EGFR is linked to cancer.